Who are Besifovir dipivoxil's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NAs+IFN-α, Telbivudine treatment, Tacrolimus &entecavir, Telbivudine (Standard of Care), Telbivudine, Lamivudine, Adefovir ,Enecavir, Blank maleate entecavir tablets.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/besifovir-dipivoxil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Besifovir dipivoxil — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Besifovir dipivoxil (Besifovir dipivoxil) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleotide reverse transcriptase inhibitor. Area: Virology / Hepatology.

marketed Nucleotide reverse transcriptase inhibitor Hepatitis B virus reverse transcriptase Virology / Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

Besifovir dipivoxil (Besifovir dipivoxil) — IlDong Pharmaceutical Co Ltd. Besifovir dipivoxil is a nucleotide reverse transcriptase inhibitor that blocks hepatitis B virus replication by inhibiting the viral reverse transcriptase enzyme.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Besifovir dipivoxil TARGET	Besifovir dipivoxil	IlDong Pharmaceutical Co Ltd	marketed	Nucleotide reverse transcriptase inhibitor	Hepatitis B virus reverse transcriptase
NAs+IFN-α	NAs+IFN-α	Beijing 302 Hospital	marketed	Antiviral combination therapy	Hepatitis B virus reverse transcriptase; interferon-alpha receptor signaling
Telbivudine treatment	Telbivudine treatment	Southeast University, China	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	Hepatitis B virus reverse transcriptase
Tacrolimus &entecavir	Tacrolimus &entecavir	Guangdong Provincial People's Hospital	marketed	Combination immunosuppressant and antiviral	Calcineurin (tacrolimus); Hepatitis B virus reverse transcriptase (entecavir)
Telbivudine (Standard of Care)	Telbivudine (Standard of Care)	Nanfang Hospital, Southern Medical University	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	Hepatitis B virus reverse transcriptase
Telbivudine, Lamivudine, Adefovir ,Enecavir	Telbivudine, Lamivudine, Adefovir ,Enecavir	Shao-quan Zhang	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI)	Hepatitis B virus reverse transcriptase
Blank maleate entecavir tablets	Blank maleate entecavir tablets	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	marketed	Nucleoside reverse transcriptase inhibitor	Hepatitis B virus reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleotide reverse transcriptase inhibitor class)

GlaxoSmithKline · 2 drugs in this class
IlDong Pharmaceutical Co Ltd · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
Sun Yat-sen University · 1 drug in this class
Jiangxi Kvvit Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Besifovir dipivoxil — Competitive Intelligence Brief. https://druglandscape.com/ci/besifovir-dipivoxil. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab